Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study of Dexrazoxane or Liposomal Doxorubicin in Newly Diagnosed Diffuse Large B-cell Lymphoma at High Risk for Heart Failure Events: the CARDIOPROTECT Trial

NCT07654426 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT07654426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07654426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study of Dexrazoxane or Liposomal Doxorubicin in Newly Diagnosed Diffuse Large B-cell Lymphoma at High Risk for Heart Failure Events: the CARDIOPROTECT Trial
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
August 31, 2026
Completion date
December 31, 2035
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiotoxicity, diffuse large b-cell lymphoma (dlbcl), lymphoma